|
US20030129194A1
(en)
*
|
1997-02-13 |
2003-07-10 |
Bone Care International, Inc. |
Targeted therapeutic delivery of vitamin D compounds
|
|
JP2001511811A
(ja)
*
|
1997-02-13 |
2001-08-14 |
ボーン ケア インターナショナル インコーポレイテッド |
ビタミンd化合物の標的治療放出
|
|
US20020035071A1
(en)
*
|
1997-07-08 |
2002-03-21 |
Josef Pitha |
Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
|
|
US20060116330A1
(en)
*
|
1997-07-08 |
2006-06-01 |
The Iams Company |
Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
|
|
US8563522B2
(en)
*
|
1997-07-08 |
2013-10-22 |
The Iams Company |
Method of maintaining and/or attenuating a decline in quality of life
|
|
CA2320193A1
(en)
|
1998-02-10 |
1999-08-19 |
Welfide Corporation |
Controlled release preparation
|
|
US7122207B2
(en)
|
1998-05-22 |
2006-10-17 |
Bristol-Myers Squibb Company |
High drug load acid labile pharmaceutical composition
|
|
UA69413C2
(uk)
|
1998-05-22 |
2004-09-15 |
Брістол-Майерс Сквібб Компані |
Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
|
|
UA73092C2
(uk)
|
1998-07-17 |
2005-06-15 |
Брістол-Майерс Сквібб Компані |
Таблетка з ентеросолюбільним покриттям і спосіб її приготування
|
|
AU5758799A
(en)
*
|
1998-09-25 |
2000-04-17 |
Sankyo Company Limited |
Hmg-coa reductase inhibitor-containing preparations
|
|
AU757343B2
(en)
*
|
1998-09-28 |
2003-02-20 |
Capsugel Belgium Nv |
Enteric and colonic delivery using HPMC capsules
|
|
JP2000247911A
(ja)
|
1999-02-26 |
2000-09-12 |
Hisamitsu Pharmaceut Co Inc |
大腸用吸収促進剤
|
|
US6620834B1
(en)
|
1999-07-02 |
2003-09-16 |
Hisamitsu Pharmaceutical Co., Inc. |
Medicinal compositions for treating colorectal cancer
|
|
EP1261316B1
(de)
*
|
2000-02-28 |
2008-04-23 |
PharmaKodex Limited |
Verabreichungssystemen für oral anzuwendende arzneimittel
|
|
TWI241195B
(en)
*
|
2000-04-10 |
2005-10-11 |
Shionogi & Co |
Preventive agent for bile acidic diarrhea
|
|
WO2001095912A1
(fr)
*
|
2000-06-16 |
2001-12-20 |
Mitsubishi Pharma Corporation |
Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
|
|
US7842308B2
(en)
*
|
2001-01-30 |
2010-11-30 |
Smithkline Beecham Limited |
Pharmaceutical formulation
|
|
GB0102342D0
(en)
*
|
2001-01-30 |
2001-03-14 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
|
US7883721B2
(en)
*
|
2001-01-30 |
2011-02-08 |
Smithkline Beecham Limited |
Pharmaceutical formulation
|
|
US7316819B2
(en)
*
|
2001-03-08 |
2008-01-08 |
Unigene Laboratories, Inc. |
Oral peptide pharmaceutical dosage form and method of production
|
|
US20030070584A1
(en)
|
2001-05-15 |
2003-04-17 |
Cynthia Gulian |
Dip coating compositions containing cellulose ethers
|
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
|
US8309118B2
(en)
|
2001-09-28 |
2012-11-13 |
Mcneil-Ppc, Inc. |
Film forming compositions containing sucralose
|
|
JP4031232B2
(ja)
*
|
2001-11-09 |
2008-01-09 |
カプスゲル・ジャパン株式会社 |
新規カプセル
|
|
US7101565B2
(en)
|
2002-02-05 |
2006-09-05 |
Corpak Medsystems, Inc. |
Probiotic/prebiotic composition and delivery method
|
|
US20030181488A1
(en)
*
|
2002-03-07 |
2003-09-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
|
|
US6982253B2
(en)
*
|
2002-06-05 |
2006-01-03 |
Supergen, Inc. |
Liquid formulation of decitabine and use of the same
|
|
US7429619B2
(en)
|
2002-08-02 |
2008-09-30 |
Mcneil Consumer Healthcare |
Polyacrylic film forming compositions
|
|
US8168170B2
(en)
*
|
2002-10-03 |
2012-05-01 |
The Procter And Gamble Company |
Compositions having an inner core and at least three surrounding layers
|
|
MY148805A
(en)
*
|
2002-10-16 |
2013-05-31 |
Takeda Pharmaceutical |
Controlled release preparation
|
|
US7320583B2
(en)
*
|
2003-04-16 |
2008-01-22 |
Frito-Lay North America, Inc |
Apparatus and method for producing colored extruded food products
|
|
TW200526274A
(en)
*
|
2003-07-21 |
2005-08-16 |
Smithkline Beecham Plc |
Pharmaceutical formulations
|
|
GB0320522D0
(en)
|
2003-09-02 |
2003-10-01 |
Glaxo Group Ltd |
Formulation
|
|
US8877178B2
(en)
|
2003-12-19 |
2014-11-04 |
The Iams Company |
Methods of use of probiotic bifidobacteria for companion animals
|
|
US20050152884A1
(en)
*
|
2003-12-19 |
2005-07-14 |
The Procter & Gamble Company |
Canine probiotic Bifidobacteria globosum
|
|
US8894991B2
(en)
*
|
2003-12-19 |
2014-11-25 |
The Iams Company |
Canine probiotic Lactobacilli
|
|
US7785635B1
(en)
|
2003-12-19 |
2010-08-31 |
The Procter & Gamble Company |
Methods of use of probiotic lactobacilli for companion animals
|
|
US20050158294A1
(en)
*
|
2003-12-19 |
2005-07-21 |
The Procter & Gamble Company |
Canine probiotic Bifidobacteria pseudolongum
|
|
TW201240679A
(en)
|
2004-03-12 |
2012-10-16 |
Capsugel Belgium Nv |
Pharmaceutical formulations
|
|
US20050283097A1
(en)
*
|
2004-06-18 |
2005-12-22 |
Ultrastop Ltd. |
Devices and methodologies useful in non invasive termination of pregnancy
|
|
DE102004046102B4
(de)
*
|
2004-09-23 |
2009-09-03 |
Mars Inc. |
Indikatorgranulat
|
|
GB0427456D0
(en)
*
|
2004-12-15 |
2005-01-19 |
Phoqus Pharmaceuticals Ltd |
Formulation for production of capsule shells and capsules
|
|
EP1885383B1
(de)
*
|
2005-05-31 |
2016-09-21 |
IAMS Europe B.V. |
Katzen probiotisches bifidobacterium
|
|
EP2261323A1
(de)
*
|
2005-05-31 |
2010-12-15 |
The Iams Company |
Probiotische Katzen-Laktobazillen
|
|
US20070014847A1
(en)
*
|
2005-07-05 |
2007-01-18 |
Ahmed Salah U |
Coated capsules and methods of making and using the same
|
|
TW200808380A
(en)
*
|
2006-02-21 |
2008-02-16 |
Shinetsu Chemical Co |
Enteric-coated preparation for site-specific delivery of drug to site within the small intestine
|
|
EP2124966B1
(de)
|
2007-02-01 |
2015-09-09 |
IAMS Europe B.V. |
Verfahren zur verringerung von entzündung und oxidativem stress bei einem säugetier mit glucose-antimetaboliten, avocado oder avocado-extrakten
|
|
EP2234963B1
(de)
|
2007-12-28 |
2020-04-08 |
Impax Laboratories, LLC |
Levodopa-formulierungen mit gesteuerter freisetzung und ihre verwendung
|
|
GB0808537D0
(en)
|
2008-05-12 |
2008-06-18 |
Archimedes Dev Ltd |
Compositions
|
|
US9771199B2
(en)
|
2008-07-07 |
2017-09-26 |
Mars, Incorporated |
Probiotic supplement, process for making, and packaging
|
|
EP2385826A4
(de)
*
|
2009-01-09 |
2012-04-04 |
Mayo Foundation |
Verfahren und materialien zur abgabe von gallensäuren
|
|
US10104903B2
(en)
|
2009-07-31 |
2018-10-23 |
Mars, Incorporated |
Animal food and its appearance
|
|
WO2012024767A1
(en)
*
|
2010-08-25 |
2012-03-01 |
Grant Rufus Sparling Ii |
Improved enteric active substance delivery
|
|
AU2012305915B2
(en)
|
2011-09-07 |
2017-09-07 |
Roland Saur-Brosch |
Formulation for the controlled release of one or several substances in the digestive tract of a mammal
|
|
US10653631B2
(en)
|
2011-09-07 |
2020-05-19 |
Roland SAUR-BROSCH |
Optimal colon targeting technology
|
|
DE102011082716A1
(de)
*
|
2011-09-14 |
2013-03-14 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Indikatorelement mit einer von einer in kontakt zu bringenden substanz abhängigen farbgebung
|
|
MX393588B
(es)
|
2013-10-07 |
2025-03-04 |
Impax Laboratories Llc |
Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos
|
|
US10987313B2
(en)
|
2013-10-07 |
2021-04-27 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
|
KR102360119B1
(ko)
|
2016-04-08 |
2022-02-09 |
주식회사 다이셀 |
셀룰로오스에스테르와 그의 성형체
|
|
TWI793141B
(zh)
|
2017-07-11 |
2023-02-21 |
日商快力膠囊股份有限公司 |
腸溶性硬質膠囊
|
|
EP3485879A1
(de)
*
|
2017-11-17 |
2019-05-22 |
Maat Pharma |
Orale pharmazeutische formulierung enthaltend bakterien
|
|
CN112105347A
(zh)
*
|
2018-05-03 |
2020-12-18 |
兆瓦恩卡普有限公司 |
将药物递送至下消化道的剂型
|
|
US12280153B2
(en)
|
2018-06-22 |
2025-04-22 |
Qualicaps Co., Ltd. |
Enteric hard capsule
|
|
US20210369625A1
(en)
*
|
2018-10-02 |
2021-12-02 |
Qualicaps Co., Ltd. |
Improved-strength hard capsule and production method for same
|
|
KR102106244B1
(ko)
*
|
2019-10-30 |
2020-05-04 |
한국광기술원 |
앵커를 구비하는 캡슐형 광역학 치료장치
|
|
CA3203975A1
(en)
|
2020-12-03 |
2022-06-09 |
Battelle Memorial Institute |
Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
|
|
WO2022140448A1
(en)
|
2020-12-22 |
2022-06-30 |
Amneal Pharmaceuticals Llc |
Levodopa dosing regimen
|
|
US11986449B2
(en)
|
2020-12-22 |
2024-05-21 |
Amneal Pharmaceuticals Llc |
Levodopa dosing regimen
|
|
AU2022253899A1
(en)
|
2021-04-07 |
2023-10-26 |
Battelle Memorial Institute |
Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
|
|
US11896719B2
(en)
|
2022-01-24 |
2024-02-13 |
Calliditas Therapeutics Ab |
Pharmaceutical compositions
|
|
EP4493165A1
(de)
*
|
2022-03-15 |
2025-01-22 |
Evonik Operations GmbH |
Vorfunktionalisierte hartschalenkapsel mit beschleunigter wirkstofffreisetzung bei ph-wert 5 bis 5.5
|
|
JPWO2024019133A1
(de)
|
2022-07-22 |
2024-01-25 |
|
|
|
WO2025072751A1
(en)
|
2023-09-29 |
2025-04-03 |
Battelle Memorial Institute |
Polymer nanoparticle compositions for in vivo expression of polypeptides
|
|
WO2025122954A1
(en)
|
2023-12-08 |
2025-06-12 |
Battelle Memorial Institute |
Use of dna origami nanostructures for molecular information based data storage systems
|